Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Disc Medicine, Inc. (IRON)
Company Research
Source: GlobeNewswire
Top-line results from AURORA, the placebo-controlled phase 2 study of bitopertin in erythropoietic porphyrias (EPP), expected March / April 2024On track to deliver multiple read-outs in 2024, including updated results from phase 1b/2 study of DISC-0974 in anemia of myelofibrosis (MF) 1H’24Strengthened leadership team with the appointments of Jean Franchi as Chief Financial Officer and Pamela Stephenson as Chief Commercial Officer, and the promotion of Jonathan Yu to Chief Operating OfficerWell-capitalized, ending 2023 with approximately $360M in cash and cash equivalents, which provides runway well into 2026 WATERTOWN, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided an
Show less
Read more
Impact Snapshot
Event Time:
IRON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IRON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IRON alerts
High impacting Disc Medicine, Inc. news events
Weekly update
A roundup of the hottest topics
IRON
News
- Disc Medicine, Inc. (NASDAQ: IRON) had its price target raised by analysts at Stifel Nicolaus from $71.00 to $73.00. They now have a "buy" rating on the stock.MarketBeat
- Disc Medicine, Inc. (NASDAQ: IRON) had its price target lowered by analysts at Morgan Stanley from $75.00 to $40.00. They now have an "equal weight" rating on the stock.MarketBeat
- Disc Medicine, Inc. (NASDAQ: IRON) had its price target lowered by analysts at BMO Capital Markets from $80.00 to $50.00. They now have an "outperform" rating on the stock.MarketBeat
- Disc Medicine, Inc. (NASDAQ: IRON) had its price target lowered by analysts at Stifel Nicolaus from $104.00 to $71.00. They now have a "buy" rating on the stock.MarketBeat
- Attention Disc Medicine, Inc. Investors: Company Investigated by the Portnoy Law FirmGlobeNewswire
IRON
Earnings
- 11/9/23 - Beat
IRON
Sec Filings
- 5/3/24 - Form 4
- 5/1/24 - Form DEF
- 5/1/24 - Form ARS
- IRON's page on the SEC website